about
Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangementsDirect or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2.Brief Report: Methotrexate Prevents Wear Particle-Induced Inflammatory Osteolysis in Mice Via Activation of Adenosine A2A Receptor.Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.Adenosine A2A receptor plays an important role in radiation-induced dermal injuryActivation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocationNew treatments for ocular hypertension.Adenosine A2A receptor (A2AR) is a fine-tune regulator of the collagen1:collagen3 balanceAdenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3.Effect of melatonin and analogues on corneal wound healing: involvement of Mt2 melatonin receptor.Unexpected Bone Formation Produced by RANKL Blockade.Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism.Bone regeneration in critical bone defects using three-dimensionally printed β-tricalcium phosphate/hydroxyapatite scaffolds is enhanced by coating scaffolds with either dipyridamole or BMP-2.Netrin-1 is highly expressed and required in inflammatory infiltrates in wear particle-induced osteolysis.Adenosine A2A receptor promotes collagen type III synthesis via β-catenin activation in human dermal fibroblasts.Netrin-1 and its receptor Unc5b are novel targets for the treatment of inflammatory arthritis.The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.Adenosine A2A receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis.The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits.The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation.Microbiological and cellular evaluation of fluorine-phosphorus doped titanium alloy: A novel antibacterial and osteostimulatory biomaterial with potential applications in orthopedic surgeryValidation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout SynovitisLocal delivery of adenosine receptor agonists to promote bone regeneration and defect healingStaphylococcus aureus Prosthetic Joint Infection Is Prevented by a Fluorine- and Phosphorus-Doped Nanostructured Ti-6Al-4V Alloy Loaded With Gentamicin and VancomycinTenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in MiceChondrocyte enlargement is a marker of osteoarthritis severityTreating osteoporotic osteoarthritis, or the art of cutting a balding man's hairFunctionalization of sol-gel coatings with organophosphorus compounds for prosthetic devices
P50
Q34356123-CDEC4D72-B95A-4A88-9708-20BA1DDC101FQ35410561-33AF67D6-2DAB-40BA-ADAE-1DE98FFA77D6Q35768206-F140819F-B381-44AC-9C38-5B771FA3ED6DQ36061710-6DE98055-20FE-430B-84E8-345668CDA36AQ36385392-734C524D-8629-40EC-983C-A3C3A8853445Q37318889-060E7400-9C1B-4B1E-A405-911E9AD61DF3Q37379504-2916FCB2-4C2B-4774-9D67-588659C24541Q37468682-A9B7C78F-28E0-49B0-B6E8-0DB77287BCC3Q37503660-61300F4B-AFA2-40FA-B92B-AD1B292404BDQ38988747-98D5732C-1F5A-4C87-ABA3-BEDA0C1EAC41Q39451226-2473BE34-7BE0-4743-8272-561DE7D7706AQ40471318-636069DE-AFE9-4C05-95A5-3BCB0540B541Q40932491-222523BC-E658-4B9B-B5A8-B8A6D4710880Q42014185-2F42E977-07DF-45F5-A6E9-13ACCFDC5463Q42693725-C9601C0E-2728-48FA-A2DC-0C453C9D014BQ42705479-C663EBC5-90A6-4836-8B78-79346AEBAA87Q46837128-BCA15C7D-D976-4BC0-872C-1084534F444CQ49374355-2385B48E-C350-4EDA-934D-6A3BE2E6A709Q51327128-69BA8369-1923-4DAC-97B2-1D4EE9E3B552Q52587889-C6A85E10-7EDC-4DFF-AAB3-6B1569DAF723Q58112623-C79B7353-CCE8-4A75-82E3-B4DC7458D814Q88497221-D574EAB3-1F5D-4390-9696-FD6D33BADEC0Q89138191-B8AD473A-CB0D-4059-9A85-BFBD4697A3F0Q90683639-5169D1FE-0D60-4080-94C8-EB2EC2A2D4DDQ91055958-4C7914B0-6220-4177-83BD-1D288F4C844FQ91733533-B5145FBA-A369-4022-9C1E-9481F0A2591DQ92168941-F390B7C0-ACD1-4DFA-BE22-05A0AB96A885Q92420775-75CFDD23-D95F-4AA0-BFA1-A71EA73E82C2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Aránzazu Mediero
@en
Aránzazu Mediero
@nl
type
label
Aránzazu Mediero
@en
Aránzazu Mediero
@nl
prefLabel
Aránzazu Mediero
@en
Aránzazu Mediero
@nl
P31
P496
0000-0002-5368-574X